New cancer drug AUR109 tested in three tumor types – trial halted early

NCT ID NCT06760702

Terminated Disease control Sponsor: Aurigene Discovery Technologies Limited Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tested three doses of the experimental drug AUR109 in 29 adults with advanced colorectal, ovarian, or kidney cancer who had already tried at least two other treatments. The goal was to see if the drug could shrink tumors and to check its safety. The trial was terminated early, so the full picture is not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AUR109 (an oral drug taken once daily)
What this could lead to: If successful, this could point toward a new treatment option for advanced colorectal, ovarian, or renal cancers.
What could go wrong: The trial was terminated early with only 29 participants, so results are limited. It is unclear if AUR109 is effective or safe at the doses tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm kidney cancer ovarian cancer ovarian carcinoma renal carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER OVARIAN CANCER RENAL CANCER

Contacts and locations

Locations

Gindodi Devi Hospital

Khursīpār, Chhattisgarh, 490012, India
Kiran Multi Super Speciality Hospital and Research Centre

Surat, Gujarat, 395004, India
Sujan Surgical Cancer Hospital and Amravati Cancer Foundation

Amravati, Maharashtra, 444605, India
Sunshine Global Hospitals

Surat, Gujarat, 395007, India
Uro-Science Centre, S.P. Medical College & AG of Hospitals

Bikaner, Rajasthan, 334003, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.